Literature DB >> 4977282

Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

E C Gotschlich, T Y Liu, M S Artenstein.   

Abstract

The group-specific polysaccharides of group A and group C meningococci have been isolated by a new procedure which employs the cationic detergent Cetavlon to precipitate these polysaccharides from the whole culture. The A and C polysaccharide prepared by this method are noteworthy because they are of high molecular weight. The main constituent of the A polysaccharide is N-acetyl, O-acetyl mannosamine phosphate; of the C polysaccharide N-acetyl, O-acetyl neuraminic acid. This purification procedure, when applied to cultures of group B organisms, yields a polysaccharide consisting primarily of N-acetyl neuraminic acid. A passive hemagglutination test developed to measure antibodies to the polysaccharides demonstrated the specificity of these antigens. Using a hemagglutination inhibition test, these antigens were again found to be group-specific, and this test could be used for serogrouping meningococcal isolates.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4977282      PMCID: PMC2138651          DOI: 10.1084/jem.129.6.1349

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  13 in total

1.  Serological typing of meningococci by means of micro-precipitation.

Authors:  K W SLATERUS
Journal:  Antonie Van Leeuwenhoek       Date:  1961       Impact factor: 2.271

2.  Biosynthesis of sialic acids by Neisseria meningitidis.

Authors:  R S BLACKLOW; L WARREN
Journal:  J Biol Chem       Date:  1962-11       Impact factor: 5.157

3.  The specific hapten of group C (group II alpha) meningococcus. I. Preparation and immunological behavior.

Authors:  R G WATSON; H W SCHERP
Journal:  J Immunol       Date:  1958-10       Impact factor: 5.422

4.  The specific hapten of group C (group II alpha) meningococcus. II. Chemical nature.

Authors:  R G WATSON; G V MARINETTI; H W SCHERP
Journal:  J Immunol       Date:  1958-10       Impact factor: 5.422

5.  Analysis of hexose phosphates and sugar mixtures with the anthrone reagent.

Authors:  L C MOKRASCH
Journal:  J Biol Chem       Date:  1954-05       Impact factor: 5.157

6.  Growth Requirements of the Meningococcus.

Authors:  I D Frantz
Journal:  J Bacteriol       Date:  1942-06       Impact factor: 3.490

7.  The isolation of porcine ribonuclease, a glycoprotein, from pancreatic juice.

Authors:  V N Reinhold; F T Dunne; J C Wriston; M Schwarz; L Sarda; C H Hirs
Journal:  J Biol Chem       Date:  1968-12-25       Impact factor: 5.157

8.  Hemagglutination with aldehyde-fixed erythrocytes for assay of antigens and antibodies.

Authors:  D H Bing; J G Weyand; A B Stavitsky
Journal:  Proc Soc Exp Biol Med       Date:  1967-04

9.  STUDIES ON MENINGOCOCCAL INFECTION : XII. IMMUNOCHEMICAL STUDIES ON MENINGOCOCCUS TYPE II.

Authors:  A E Menzel; G Rake
Journal:  J Exp Med       Date:  1942-04-01       Impact factor: 14.307

10.  STUDIES ON MENINGOCOCCUS INFECTION : VIII. THE TYPE I SPECIFIC SUBSTANCE.

Authors:  H W Scherp; G Rake
Journal:  J Exp Med       Date:  1935-05-31       Impact factor: 14.307

View more
  117 in total

1.  Induction of a protective capsular polysaccharide antibody response to a multiepitope DNA vaccine encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide.

Authors:  Deborah M Prinz; S Louise Smithson; Thomas Kieber-Emmons; M A Julie Westerink
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

Review 2.  The development of vaccines: how the past led to the future.

Authors:  Stanley A Plotkin; Susan L Plotkin
Journal:  Nat Rev Microbiol       Date:  2011-10-03       Impact factor: 60.633

Review 3.  Serogroup A meningococcal conjugate vaccines: building sustainable and equitable vaccine strategies.

Authors:  Amy C Sherman; David S Stephens
Journal:  Expert Rev Vaccines       Date:  2020-04-29       Impact factor: 5.217

4.  A universal vaccine for serogroup B meningococcus.

Authors:  Marzia M Giuliani; Jeannette Adu-Bobie; Maurizio Comanducci; Beatrice Aricò; Silvana Savino; Laura Santini; Brunella Brunelli; Stefania Bambini; Alessia Biolchi; Barbara Capecchi; Elena Cartocci; Laura Ciucchi; Federica Di Marcello; Francesca Ferlicca; Barbara Galli; Enrico Luzzi; Vega Masignani; Davide Serruto; Daniele Veggi; Mario Contorni; Maurizio Morandi; Alessandro Bartalesi; Vanda Cinotti; Donatella Mannucci; Francesca Titta; Elisa Ovidi; Jo Anne Welsch; Dan Granoff; Rino Rappuoli; Mariagrazia Pizza
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-06       Impact factor: 11.205

5.  Neuraminidase associated with coliphage E that specifically depolymerizes the Escherichia coli K1 capsular polysaccharide.

Authors:  S Tomlinson; P W Taylor
Journal:  J Virol       Date:  1985-08       Impact factor: 5.103

6.  Comparison of radioimmunoassay and enzyme-linked immunosorbent assay in measurement of antibodies to Neisseria meningitidis group A capsular polysaccharide.

Authors:  E C Beuvery; M H Kayhty; A B Leussink; V Kanhai
Journal:  J Clin Microbiol       Date:  1984-10       Impact factor: 5.948

7.  Purification and vaccine potential of Klebsiella capsular polysaccharides.

Authors:  S J Cryz; E Fürer; R Germanier
Journal:  Infect Immun       Date:  1985-10       Impact factor: 3.441

8.  Enzyme-linked immunosorbent assay for detection and quantitation of capsular antigen of Haemophilus influenzae type b.

Authors:  F J Crosson; J A Winkelstein; E R Moxon
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

Review 9.  Meningococcal vaccines.

Authors:  Jens U Rüggeberg; Andrew J Pollard
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

10.  Meningococcal infections. 5. Duration of polysaccharide-vaccine-induced antibody.

Authors:  M S Artenstein
Journal:  Bull World Health Organ       Date:  1971       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.